Dr. Reddy's Laboratories Ltd.
NSE: DRREDDY · Pharmaceuticals
Snapshot
Unlock Dr. Reddy's Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Dr. Reddy's Laboratories is an integrated pharmaceutical company that develops, manufactures, and markets a wide range of finished dosage forms, active pharmaceutical ingredients, and biologics. The company operates globally across segments including Global Generics, Pharmaceutical Services and Active Ingredients, and Proprietary Products.
Business Model
The company generates revenue through the sale of branded and generic prescription drugs, over-the-counter products, and active pharmaceutical ingredients. It also leverages contract research services and strategic licensing agreements to monetise its research and development capabilities.
Growth Outlook
Growth is driven by the expansion of its biologics portfolio and the development of differentiated formulations in oncology and inflammation. Strategic collaborations, such as the partnership with Curis, Inc., aim to advance precision oncology targets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards can lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical market often leads to significant price erosion and margin compression.
- R&D Uncertainty. Investments in proprietary products and novel therapies carry inherent risks regarding clinical trial success and regulatory approval timelines.
- Litigation Risk. The pharmaceutical sector is frequently subject to intellectual property litigation and patent challenges that can impact product commercialisation.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Dr. Reddy's Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹33,700 Cr
TTM · consolidated
NET PROFIT
₹4,158 Cr
TTM · consolidated
EPS
₹50.40
TTM · consolidated
RETURN ON EQUITY
12.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.3%
TTM · consolidated
P/E
24.3x
Q4 FY26 · consolidated
EV/EBITDA
13.7x
Q4 FY26 · consolidated
EBITDA MARGIN
23.2%
TTM · consolidated
NET PROFIT MARGIN
2.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Dr. Reddy's Laboratories Ltd.DRREDDY | 1,04,598 | 24.29 | 13.66 | 3.2% | 23.2% | 12.0% | 15.3% | -2.8% |
Lupin Ltd.LUPIN | 1,06,687 | 21.42 | 12.56 | 23.1% | 33.1% | 28.9% | 33.8% | +29.6% |
Cipla Ltd.CIPLA | 99,316 | 29.76 | 16.96 | 2.2% | 24.0% | 12.1% | 16.1% | -3.1% |
Zydus Lifesciences Ltd.ZYDUSLIFE | 89,212 | 23.03 | 14.03 | 16.8% | 33.1% | 20.7% | 23.3% | +19.1% |
Mankind Pharma Ltd.MANKIND | 81,112 | 54.93 | 27.93 | 16.3% | 27.8% | 13.1% | 13.5% | -3.0% |
Aurobindo Pharma Ltd.AUROPHARMA | 74,365 | 25.66 | 12.21 | 6.1% | 21.8% | 10.3% | 15.1% | +34.3% |
As of Q4 FY26
Financials
Dr. Reddy's Laboratories Ltd.
NSE: DRREDDY · Pharmaceuticals
Snapshot
Unlock Dr. Reddy's Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Dr. Reddy's Laboratories is an integrated pharmaceutical company that develops, manufactures, and markets a wide range of finished dosage forms, active pharmaceutical ingredients, and biologics. The company operates globally across segments including Global Generics, Pharmaceutical Services and Active Ingredients, and Proprietary Products.
Business Model
The company generates revenue through the sale of branded and generic prescription drugs, over-the-counter products, and active pharmaceutical ingredients. It also leverages contract research services and strategic licensing agreements to monetise its research and development capabilities.
Growth Outlook
Growth is driven by the expansion of its biologics portfolio and the development of differentiated formulations in oncology and inflammation. Strategic collaborations, such as the partnership with Curis, Inc., aim to advance precision oncology targets.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where any failure to meet manufacturing standards can lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical market often leads to significant price erosion and margin compression.
- R&D Uncertainty. Investments in proprietary products and novel therapies carry inherent risks regarding clinical trial success and regulatory approval timelines.
- Litigation Risk. The pharmaceutical sector is frequently subject to intellectual property litigation and patent challenges that can impact product commercialisation.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Dr. Reddy's Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹33,700 Cr
TTM · consolidated
NET PROFIT
₹4,158 Cr
TTM · consolidated
EPS
₹50.40
TTM · consolidated
RETURN ON EQUITY
12.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.3%
TTM · consolidated
P/E
24.3x
Q4 FY26 · consolidated
EV/EBITDA
13.7x
Q4 FY26 · consolidated
EBITDA MARGIN
23.2%
TTM · consolidated
NET PROFIT MARGIN
2.9%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.2x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26